Dr. Nobuko Hijiya, MD
Claim this profileNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Expert in Cancer
Expert in Brain Tumor
42 reported clinical trials
94 drugs studied
About Nobuko Hijiya, MD
Education:
- Earned an MD (Doctor of Medicine) from an unspecified institution.
Experience:
- Specializes in Pediatric Hematology-Oncology at NewYork-Presbyterian/Columbia University Medical Center.
- Affiliated with the Herbert Irving Comprehensive Cancer Center.
- Focuses on leukemias and lymphomas in children, adolescents, and young adults, with a particular interest in chronic myeloid leukemia (CML).
- Actively involved in clinical research, particularly in studies on combination therapies for relapsed acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).
- Serves as a professor and section head of pediatric oncology, mentoring the next generation of medical professionals.
Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Brain Tumor
Global LeaderStage I
Stage II
Stage IV
Affiliated Hospitals
Clinical Trials Nobuko Hijiya, MD is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Selinexor + Radiation
for Brain Cancer
This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
Recruiting1 award Phase 1 & 21 criteria
More about Nobuko Hijiya, MD
Clinical Trial Related8 years of experience running clinical trials · Led 42 trials as a Principal Investigator · 18 Active Clinical TrialsTreatments Nobuko Hijiya, MD has experience with
- Cyclophosphamide
- Nivolumab
- Radiation Therapy
- Etoposide
- Doxorubicin Hydrochloride
- Vincristine
Breakdown of trials Nobuko Hijiya, MD has run
Brain Tumor
Neuroblastoma
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nobuko Hijiya, MD specialize in?
Nobuko Hijiya, MD focuses on Cancer and Brain Tumor. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage I.
Is Nobuko Hijiya, MD currently recruiting for clinical trials?
Yes, Nobuko Hijiya, MD is currently recruiting for 18 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Nobuko Hijiya, MD has studied deeply?
Yes, Nobuko Hijiya, MD has studied treatments such as Cyclophosphamide, Nivolumab, Radiation Therapy.
What is the best way to schedule an appointment with Nobuko Hijiya, MD?
Apply for one of the trials that Nobuko Hijiya, MD is conducting.
What is the office address of Nobuko Hijiya, MD?
The office of Nobuko Hijiya, MD is located at: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York 10032 United States. This is the address for their practice at the NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.